XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -192.98%-3.24M | -118.85%-8.46M | -113.50%-2.51M | -108.12%-2.54M | -172.52%-2.3M | -77.29%-1.11M | -3.87M | -1.18M | -1.22M | -844.88K |
Net income from continuing operations | -136.95%-3.11M | -62.41%-10.15M | -85.10%-2.49M | -72.92%-4.67M | -10.34%-1.68M | -92.06%-1.31M | ---6.25M | ---1.35M | ---2.7M | ---1.52M |
Depreciation and amortization | --63.89K | --106.93K | --53.03K | --42.02K | --11.88K | --0 | --0 | --0 | --0 | ---- |
Other non cash items | ---- | --786.5K | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Change In working capital | -193.17%-193.06K | 40,417.28%473.73K | -140.37%-239.45K | 3,887.01%1.3M | -966.60%-789.18K | 925.22%207.21K | ---1.18K | ---99.62K | --32.48K | --91.07K |
-Change in prepaid assets | -7,021.90%-789.75K | -876.51%-863.33K | -509.70%-303.76K | 288.43%104.79K | -2,292.24%-653.27K | 13.20%-11.09K | ---88.41K | ---49.82K | ---55.61K | --29.8K |
-Change in payables and accrued expense | -48.34%112.77K | 543.64%561.47K | 1,214.33%554.87K | -205.45%-92.9K | -293.90%-118.8K | 1,869.77%218.3K | --87.23K | ---49.79K | --88.1K | --61.27K |
-Change in other current liabilities | --483.92K | --775.58K | ---490.56K | --1.28M | ---17.11K | --0 | --0 | --0 | --0 | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -192.98%-3.24M | -118.85%-8.46M | -113.50%-2.51M | -108.12%-2.54M | -172.52%-2.3M | -77.29%-1.11M | ---3.87M | ---1.18M | ---1.22M | ---844.88K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -3.56M | -3.7M | 0 | 0 | ||||||
Net PPE purchase and sale | ---- | ---1.7M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Net investment purchase and sale | ---- | ---2M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Net other investing changes | ---3.56M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | ---3.56M | ---3.7M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 4,850.82%101.56M | 288.00%33.72M | 20.93M | 49.99%10.38M | 39.81%360K | 35.60%2.05M | 8.69M | 0 | 6.92M | 257.5K |
Net common stock issuance | 4,713.82%101.4M | 298.77%34.95M | --20.7M | 69.73%11.79M | 17.07%360K | 39.23%2.11M | --8.77M | --0 | --6.95M | --307.5K |
Proceeds from stock option exercised by employees | --9.22M | --2.32M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Net other financing activities | -16,370.65%-9.06M | -4,639.77%-3.55M | ---2.09M | -5,533.62%-1.41M | --0 | ---55K | ---75K | --0 | ---25K | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 4,850.82%101.56M | 288.00%33.72M | --20.93M | 49.99%10.38M | 39.81%360K | 35.60%2.05M | --8.69M | --0 | --6.92M | --257.5K |
Net cash flow | ||||||||||
Beginning cash position | 310.01%28.51M | 226.42%6.95M | 69.64%13.79M | 144.94%5.96M | 161.63%7.9M | 226.42%6.95M | --2.13M | --8.13M | --2.43M | --3.02M |
Current changes in cash | 9,930.70%94.76M | 346.93%21.55M | 1,351.72%14.72M | 37.51%7.83M | -230.70%-1.94M | 6.31%944.7K | --4.82M | ---1.18M | --5.7M | ---587.38K |
End cash Position | 1,460.84%123.27M | 310.01%28.51M | 310.01%28.51M | 69.64%13.79M | 144.94%5.96M | 161.63%7.9M | --6.95M | --6.95M | --8.13M | --2.43M |
Free cash flow | -192.98%-3.24M | -162.80%-10.16M | -258.08%-4.21M | -108.12%-2.54M | -172.52%-2.3M | -77.29%-1.11M | ---3.87M | ---1.18M | ---1.22M | ---844.88K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |